A pilot study of peripheral blood stem cell harvest using bortezomib in combination with granulocyte colony stimulating factor (G-CSF)

A pilot study of peripheral blood stem cell harvest using bortezomib in combination with granulocyte colony stimulating factor (G-CSF) - Peripheral blood stem cell harvest with bortezomib and G-CSF

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022421

Enrollment

Registered

2016-05-25

Start date

2016-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with multiple myeloma who are eligible for transplantation

Interventions

G-CSF at a dose of 200 ug/m2 was given subcutaneously twice daily on day 1 to 5, and bortezomib at a dose of 1.3 mg/m2 was administered intravenously on day 4. Peripheral blood stem cells were collect

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with multiple myeloma who are eligible for transplantation Patients aged 20 years or older Patients with normal organ function

Exclusion criteria

Exclusion criteria: Patients who are hypersensitive for either bortezomib or G-CSF Patients with grade 2 or higher peripheral neuropathy Patients with double cancer Patients with psychological disorder Patients with interstitial pneumonia

Design outcomes

Primary

Measure	Time frame
Proportion of patients who are able to obtain more than 1.5 x10^6/kg of CD34-positive cells at one apheresis	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactYasushi Takamatsu

Fukuoka University Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine

yasushi@fukuoka-u.ac.jp092-801-1011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026